Hiroshi Tanaka

3PUBLICATIONS
41CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Nanomedicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|Sep 25, 2025
Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1-Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study.

Kohei Shitara, Motohiro Tamiya, Kyoichi Okishio

|Mar 31, 2025
Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non-Small Cell Lung Cancer Harboring EGFR Mutation.

Shintaro Kanda, Seiji Niho, Takayasu Kurata

|Jun 06, 2019
Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT).

Morihito Okada, Takashi Kijima, Keisuke Aoe

Pageof 1

Frequent Collaborators

1 joint publications

Takashi Kijima

1 joint publications

Nobukazu Fujimoto

1 joint publications

Kazuhiko Nakagawa

1 joint publications

Yuichiro Takeda